China Interventional Cardiovascular Device Industry Report, 2014-2017
NEW
YORK, The prevalence of
cardiovascular disease in China impacted
by accelerated aging of population and changes in consumption concept, dietary
habit, way of working and other lifestyles has been growing year after year,
thereby promoting the development of domestic percutaneous coronary
intervention (PCI) market. PCI cases in China totaled
454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional
cardiovascular device industry there was worth RMB20.12 billion.
At
present, half of the Chinese interventional cardiovascular device industry is
dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech
Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was
controlled by domestic companies, 31.2% by foreign counterparts represented by
Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and
Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.
Interventional
cardiovascular devices in China include
cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices,
etc., among which cardiovascular stent is predominant.
Cardiovascular
stent: In 2013, the Chinese cardiovascular stent market equaledRMB11.2 billion, 78.8% of which was occupied by domestic
drug-eluting stents. That same year, 686,000 units of cardiovascular stent were
consumed in China, up 11.7% year on year, and drug-eluting stents
accounted for 99.5%, indicating that the drug-eluting stent is gradually
becoming an important device for interventional cardiovascular therapy.
In
addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop
biodegradable stents, which are expected to be available on the market in 2017.
Thanks to its excellent performance, biodegradable stents are likely to replace
drug-eluting stents gradually in the future, thus becoming the main variety in
domestic coronary stent market.
Balloon
catheter: In 2013, China's demand
for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which
were PTCA balloon catheters for dilatation. With rapid development of local
PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW
Medical, domestic PTCA balloon catheters increased its market share from 20% in
2009 to 40% in 2013.
Affected
by the implementation of "Regulations on the Centralized Procurement of
High-value Medical Consumables", purchase price of interventional
cardiovascular devices will continue to decline, further squeezing profit
margins of relevant companies. However, the substantial decline in prices will
enable more patients to receive PCI, thus helping the industry maintain a
fairly rapid growth rate. It is expected that the Chinese interventional
cardiovascular device market will worthRMB41.2 billion by
2017.
China
Interventional Cardiovascular Device Industry Report, 2014-2017 focuses on the
following:
Status
quo of China interventional
cardiovascular device industry, including overview, market demand, import &
export, competitive landscape and entry barriers;
Development
environment of China interventional
cardiovascular device industry, embracing macro environment, policy climate and
upstream & downstream sectors;
Status
quo, competitive landscape, etc. of China interventional
cardiovascular device market segments, covering coronary stent, balloon
catheter, catheter, guidewire, sheath group and auxiliary devices;
Operation,
interventional cardiovascular device business, etc. of 6 foreign and 12 Chinese
interventional cardiovascular device companies.
Source: Reportlinker
Comments